BioNTech
NEWS
The U.S. Food and Drug Administration posted analyses of the Pfizer-BioNTech COVID-19 vaccine in children ages 5 to 11 years old ahead of Tuesday’s vaccines advisory committee meeting.
The U.S. FDA has a busy period at the end of October heading into the first week of November.
It was yet another busy week for clinical trial news. Here’s a look.
Atreca announced it is licensing its preclinical monoclonal antibody for the prevention of malaria to the Gates Medical Research Institute (MRI) for development.
The CDC supported the FDA’s approval of mixing and matching vaccines, where eligible populations can take a booster shot from another brand different from their initial series.
The Pfizer-BioNTech mRNA COVID-19 vaccine is reportedly the top vaccine used globally. Here’s a look at today’s highlights.
The U.S. FDA approved the use of Moderna’s and Janssen’s COVID-19 vaccines as a booster dose after their primary versions are completed.
Winter is quickly approaching in the U.S. Vaccine makers aren’t taking a wait-and-see approach but actively preparing for what may come next.
A subtype of the Delta variant might be rising, although it’s not yet clear if it’s more transmissible or lethal than the original Delta variant. Read on for that and more COVID-19 news.
JOBS
IN THE PRESS